BTC Capital Management Inc. Has $420,000 Position in Novo Nordisk A/S (NVO)

BTC Capital Management Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 69.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,730 shares of the company’s stock after purchasing an additional 3,592 shares during the quarter. BTC Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $420,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Proficio Capital Partners LLC raised its position in Novo Nordisk A/S by 6.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after purchasing an additional 150 shares during the period. AlphaMark Advisors LLC raised its position in Novo Nordisk A/S by 1.1% in the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after purchasing an additional 30 shares during the period. MUFG Americas Holdings Corp raised its position in Novo Nordisk A/S by 100.0% in the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after purchasing an additional 1,500 shares during the period. Cornerstone Advisors Inc. raised its position in Novo Nordisk A/S by 1,220.2% in the 2nd quarter. Cornerstone Advisors Inc. now owns 3,525 shares of the company’s stock worth $151,000 after purchasing an additional 3,258 shares during the period. Finally, Parallel Advisors LLC raised its position in Novo Nordisk A/S by 44.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock worth $174,000 after purchasing an additional 1,264 shares during the period. Institutional investors own 6.01% of the company’s stock.

Novo Nordisk A/S (NVO) traded down $0.15 during mid-day trading on Tuesday, hitting $49.76. 895,100 shares of the company’s stock were exchanged, compared to its average volume of 2,158,519. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $50.95. The stock has a market capitalization of $127,270.50, a PE ratio of 21.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.63.

A number of brokerages recently commented on NVO. Zacks Investment Research cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Bank of America Corporation upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. BidaskClub cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $55.00.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/btc-capital-management-inc-has-420000-position-in-novo-nordisk-as-nvo.html.

In other news, insider Eric S. Sprott acquired 50,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $8.34 per share, for a total transaction of $417,000.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply